Oral gene application using chitosan-DNA nanoparticles induces transferable tolerance

Clinical and Vaccine Immunology

Volumn 19, Issue 11, 2012, Pages 1758-1764

  Goldmann, Katja ^a   Ensminger, Stephan M ^a   Spriewald, Bernd M ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN DNA NANOPARTICLE; CYTOKINE; NANOPARTICLE; OVALBUMIN; OVALBUMIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DONOR; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH1 CELL; TH2 CELL; TH3 CELL;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHITOSAN; CYTOKINES; DNA; DRUG CARRIERS; GENE TRANSFER TECHNIQUES; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED BALB C; NANOPARTICLES; OVALBUMIN; T-LYMPHOCYTES, REGULATORY;

EID: 84868260201     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00186-12     Document Type: Article

References (48)

1. Afuwape AO, Turner MW, Strobel S. 2004. Oral administration of bovine whey proteins to mice elicits opposing immunoregulatory responses and is adjuvant dependent. Clin. Exp. Immunol. 136:40-48. (Pubitemid 38437763)
2. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. 2004. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Control Release 100:5-28. (Pubitemid 39445982)
3. Bellmann K, et al. 1997. Intervention in autoimmune diabetes by targeting the gut immune system. Int. J. Immunopharmacol. 19:573-577. (Pubitemid 28261018)
4. Bivas-Benita M, et al. 2004. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLAA* 0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22:1609-1615. (Pubitemid 38447207)
5. Bowman K, Leong KW. 2006. Chitosan nanoparticles for oral drug and gene delivery. Int. J. Nanomedicine 1:117-128.
6. Bowman K, Sarkar R, Raut S, Leong KW. 2008. Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. J. Control Release 132:252-259.
7. Chaillous L, et al. 2000. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356:545-549. (Pubitemid 30611859)
8. Chen J, et al. 2004. Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J. Gastroenterol. 10:112-116. (Pubitemid 38071989)
9. Chen W, et al. 2003. Conversion of peripheral CD4+CD25-naive T cells to CD4+6CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198:1875-1886. (Pubitemid 38032120)
10. Chen Y, et al. 1996. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc. Natl. Acad. Sci. U. S. A. 93:388-391. (Pubitemid 26038164)
11. Chen Y, et al. 1995. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376:177-180.
12. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265:1237-1240. (Pubitemid 24291983)
13. Chew JL, Wolfowicz CB, Mao HQ, Leong KW, Chua KY. 2003. Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine 21:2720 -2729. (Pubitemid 36703182)
14. Choy EH, et al. 2001. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum. 44:1993-1997. (Pubitemid 33644040)
15. Dhadwar SS, Kiernan J, Wen J, Hortelano G. 2010. Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophiliaAmice. J. Thromb. Haemost. 8:2743-2750.
16. Faria AM, et al. 2003. Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/ interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J. Autoimmun. 20:135-145. (Pubitemid 36349072)
17. Faria AM, Weiner HL. 2005. Oral tolerance. Immunol. Rev. 206:232-259. (Pubitemid 41105174)
18. Frey A, Di Canzio J, Zurakowski D. 1998. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221: 35-41. (Pubitemid 29017921)
19. Friedman A, Weiner HL. 1994. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. U. S. A. 91:6688-6692. (Pubitemid 24200727)
20. Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL. 1995. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am. J. Pathol. 147:1193-1199.
21. Haneda K, et al. 1997. TGF-beta induced by oral tolerance ameliorates experimental tracheal eosinophilia. J. Immunol. 159:4484-4490. (Pubitemid 127470609)
22. Hultkrantz S, Ostman S, Telemo E. 2005. Induction of antigen-specific regulatory T cells in the liver-draining celiac lymph node following oral antigen administration. Immunology 116:362-372. (Pubitemid 41532127)
23. Jean M, Alameh M, Buschmann MD, Merzouki A. 2011. Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. Gene Ther. 18:807-816.
24. Kaneko H, et al. 2010. Efficacy of the slow dose-up method for specific oral tolerance induction in children with cow's milk allergy: comparison with reported protocols. J. Investig. Allergol. Clin. Immunol. 20:538-539.
25. Kim JH, et al. 2002. Effects of the aqueous extract of Epimedii Herba on the induction of oral tolerance in mice. Biol. Pharm. Bull. 25:1000-1005.
26. Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S. 2004. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J. Neuroimmunol. 152:112-120. (Pubitemid 38829708)
27. Mansouri S, et al. 2004. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur. J. Pharm. Biopharm. 57:1-8. (Pubitemid 38058799)
28. Mao HQ, et al. 2001. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control Release 70: 399-421.
29. Maron R, Slavin AJ, Hoffmann E, Komagata Y, Weiner HL. 2002. Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines. Int. Immunol. 14:131-138. (Pubitemid 34144737)
30. McMenamin C, Pimm C, McKersey M, Holt PG. 1994. Regulation of IgE responses to inhaled antigen in mice by antigen-specific gamma delta T cells. Science 265:1869-1871. (Pubitemid 24324243)
31. Niu L, Xu YC, Dai Z, Tang HQ. 2008. Gene therapy for type 1 diabetes mellitus in rats by gastrointestinal administration of chitosan nanoparticles containing human insulin gene. World J. Gastroenterol. 14:4209-4215.
32. Niu L, Xu YC, Xie HY, Dai Z, Tang HQ. 2008. Expression of human insulin gene wrapped with chitosan nanoparticles in NIH3T3 cells and diabetic rats. Acta Pharmacol. Sin. 29:1342-1349.
33. Ojeda P, Ojeda I, Pineda F, Alfaya T, Ojeda JA. 2010. Induction of oral tolerance to peanut: a successful home-based protocol. J. Investig. Allergol. Clin. Immunol. 20:524-528.
34. Petersen JS, et al. 2003. Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes. Clin. Exp. Immunol. 134:38-45. (Pubitemid 37186585)
35. Roy K, Mao HQ, Huang SK, Leong KW. 1999. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5:387-391. (Pubitemid 29180575)
36. Russo M, et al. 1998. Prevention of lung eosinophilic inflammation by oral tolerance. Immunol. Lett. 61:15-23. (Pubitemid 28161146)
37. Spies B, et al. 2003. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J. Immunol. 171:5908-5912. (Pubitemid 37467208)
38. Thorstenson KM, Khoruts A. 2001. Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J. Immunol. 167:188-195. (Pubitemid 32567777)
39. Trentham DE, et al. 1993. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261:1727-1730. (Pubitemid 23332920)
40. Tsuji NM, Kosaka A. 2008. Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol. 29:532-540.
41. Wang Y, Mei Y, Bao S, Xu L. 2007. Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses. Clin. Exp. Immunol. 148:178-187. (Pubitemid 46364990)
42. Weiner HL. 1994. Oral tolerance. Proc. Natl. Acad. Sci. U. S. A. 91:10762-10765. (Pubitemid 24349564)
43. Weiner HL, et al. 1993. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259:1321-1324. (Pubitemid 23100270)
44. Xi C, et al. 2009. A novel recombinant peptide containing only two T-cell tolerance epitopes of chicken type II collagen that suppresses collageninduced arthritis. Mol. Immunol. 46:729-737.
45. Xu J, et al. 2011. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae. Clin. Vaccine Immunol. 18:75-81.
46. Zavazava N, et al. 2000. Oral feeding of an immunodominant MHC donor-derived synthetic class I peptide prolongs graft survival of heterotopic cardiac allografts in a high-responder rat strain combination. J. Leukoc. Biol. 67:793-800.
47. Zhang X, Izikson L, Liu L, Weiner HL. 2001. Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J. Immunol. 167:4245-4253. (Pubitemid 32954298)
48. Zhu P, et al. 2007. Oral administration of type-II collagen peptide 250- 270 suppresses specific cellular and humoral immune response in collagen- induced arthritis. Clin. Immunol. 122:75-84. (Pubitemid 46026693)